MX2019013642A - Compuestos, composiciones y metodos. - Google Patents
Compuestos, composiciones y metodos.Info
- Publication number
- MX2019013642A MX2019013642A MX2019013642A MX2019013642A MX2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- compounds
- inflammation
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere de forma general a métodos y composiciones para prevenir o detener la muerte celular y/o la inflamación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507682P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/033269 WO2018213634A1 (en) | 2017-05-17 | 2018-05-17 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013642A true MX2019013642A (es) | 2020-07-20 |
Family
ID=64274734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013642A MX2019013642A (es) | 2017-05-17 | 2018-05-17 | Compuestos, composiciones y metodos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11174262B2 (es) |
| EP (1) | EP3625234B1 (es) |
| JP (2) | JP7140781B2 (es) |
| KR (1) | KR102637541B1 (es) |
| CN (1) | CN110914275A (es) |
| AU (2) | AU2018269745C1 (es) |
| BR (1) | BR112019023979A2 (es) |
| CA (1) | CA3063938A1 (es) |
| IL (1) | IL270505B2 (es) |
| MX (1) | MX2019013642A (es) |
| WO (1) | WO2018213634A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912295T3 (es) * | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4320057A (en) * | 1980-06-23 | 1982-03-16 | American Home Products Corporation | Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones |
| US4290952A (en) * | 1980-06-23 | 1981-09-22 | American Home Products Corporation | Aryl-1-mercaptoalkanoylproline and homoproline derivatives |
| CN1960728A (zh) | 2004-01-16 | 2007-05-09 | 密歇根大学董事会 | 构象受限的smac模拟物及其应用 |
| US20100190688A1 (en) | 2004-07-12 | 2010-07-29 | Bin Chao | Tetrapeptide analogs |
| RU2007147959A (ru) * | 2005-06-08 | 2009-07-20 | Новартис АГ (CH) | Органические соединения |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| BRPI0715195A2 (pt) | 2006-07-24 | 2013-06-11 | Tetralogic Pharm Corp | composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica |
| AU2013334707B2 (en) | 2012-10-22 | 2018-02-22 | City Of Hope | ETP derivatives |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EA201791289A1 (ru) | 2014-12-11 | 2017-12-29 | Президент Энд Феллоуз Оф Гарвард Колледж | Ингибиторы клеточного некроза и связанные с ними способы |
| KR102596723B1 (ko) * | 2014-12-24 | 2023-11-01 | 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 | 괴사 억제제 |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2018
- 2018-05-17 CA CA3063938A patent/CA3063938A1/en active Pending
- 2018-05-17 EP EP18803112.4A patent/EP3625234B1/en active Active
- 2018-05-17 CN CN201880047315.8A patent/CN110914275A/zh active Pending
- 2018-05-17 KR KR1020197036801A patent/KR102637541B1/ko active IP Right Grant
- 2018-05-17 AU AU2018269745A patent/AU2018269745C1/en active Active
- 2018-05-17 WO PCT/US2018/033269 patent/WO2018213634A1/en active Application Filing
- 2018-05-17 JP JP2019563609A patent/JP7140781B2/ja active Active
- 2018-05-17 IL IL270505A patent/IL270505B2/en unknown
- 2018-05-17 MX MX2019013642A patent/MX2019013642A/es unknown
- 2018-05-17 BR BR112019023979A patent/BR112019023979A2/pt unknown
-
2019
- 2019-11-14 US US16/683,970 patent/US11174262B2/en active Active
-
2021
- 2021-10-05 US US17/494,336 patent/US11851433B2/en active Active
-
2022
- 2022-04-14 AU AU2022202524A patent/AU2022202524B2/en active Active
- 2022-09-07 JP JP2022141824A patent/JP2022174180A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN110914275A (zh) | 2020-03-24 |
| IL270505B2 (en) | 2023-09-01 |
| JP7140781B2 (ja) | 2022-09-21 |
| AU2022202524A1 (en) | 2022-05-12 |
| AU2018269745A1 (en) | 2019-11-28 |
| US11174262B2 (en) | 2021-11-16 |
| EP3625234A4 (en) | 2021-03-10 |
| JP2022174180A (ja) | 2022-11-22 |
| WO2018213634A1 (en) | 2018-11-22 |
| KR20200006120A (ko) | 2020-01-17 |
| AU2018269745B2 (en) | 2022-01-27 |
| IL270505B1 (en) | 2023-05-01 |
| US20220024938A1 (en) | 2022-01-27 |
| KR102637541B1 (ko) | 2024-02-15 |
| CA3063938A1 (en) | 2018-11-22 |
| AU2022202524B2 (en) | 2023-10-05 |
| BR112019023979A2 (pt) | 2020-06-09 |
| EP3625234B1 (en) | 2023-09-20 |
| US11851433B2 (en) | 2023-12-26 |
| EP3625234A1 (en) | 2020-03-25 |
| US20200079784A1 (en) | 2020-03-12 |
| JP2020520925A (ja) | 2020-07-16 |
| AU2018269745C1 (en) | 2022-06-09 |
| IL270505A (es) | 2019-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018006578A (es) | Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias. | |
| MX2018005829A (es) | Composiciones para tratar el cabello. | |
| MX2017016405A (es) | Reguladores de nrf2. | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| MX2019011496A (es) | Composiciones de niraparib. | |
| PH12019550096A1 (en) | Beta-casein a2 and prevention of inflammation of the bowel | |
| EA201691194A1 (ru) | Стимуляторы ргц | |
| AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| EP3943188A3 (en) | Design, synthesis and characterization of metal organic frameworks | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| MX2016007878A (es) | Composicion farmaceutica que comprende adalimumab. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2020010657A (es) | Derivados de oxadiazolina. | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2017008414A (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2016015569A (es) | Metodos y composiciones para inmunomodulacion. | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| MX2017011521A (es) | Composiciones topicas que comprenden un corticosteroide. | |
| GB2568181A (en) | Wheat | |
| SG10201900598TA (en) | Factor viii formulation | |
| EA202090732A1 (ru) | Составы для трансдермального введения |